ABBV vs LULU: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Lululemon Athletica Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-21.
AbbVie Inc. · Healthcare
$261.70
-1.0% upside to fair value
Med Conviction
Grade C
High Quality
VS
Lululemon Athletica Inc. · Consumer Cyclical
$98.06
+1.5% upside to fair value
Low Conviction
Grade C
QuantHub Verdict
LULU has more upside to fair value
(+1.5%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
LULU |
| Current Price |
$261.70 |
$98.06 |
| Fair Value Estimate |
$259.04 |
$99.50 |
| Upside to Fair Value |
-1.0%
|
+1.5%
|
| Market Cap |
$462.4B |
$11.1B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
24.8x
|
4.6x
|
| Price / Sales |
7.2x
|
1.0x
|
| Price / FCF |
23.6x
|
8.2x
|
| Revenue Growth YoY |
+10.2%
|
-4.3%
|
| Gross Margin |
71.5%
|
56.1%
|
| Operating Margin |
29.3%
|
17.8%
|
| Return on Equity |
-136.5%
|
29.7%
|
| Dividend Yield |
2.61% |
0% |
| FCF Yield |
4.25%
|
12.24%
|
| Analyst Consensus |
Strong Buy
|
Sell
|
Investment Thesis
AbbVie is a diversified branded-biopharma company spanning immunology, neuroscience, oncology and aesthetics, with high-margin TTM economics including a 71.5% gross margin and 29.3% operating margin. Its successor immunology franchises are performing strongly: Q2 2026 revenue rose 10.2% year over year, with Skyrizi up 24.4% to $5.505 billion and Rinvoq up 24.5% to $2.525 billion, helping offset a…
Lululemon Athletica designs and retails premium athletic apparel and accessories through company-owned stores and direct-to-consumer channels, with roughly 39,000 employees and a brand built on technical fabrics and community-led fitness positioning. The business still earns high returns on equity of 29.7% and generates $12.00 of free cash flow per share on $97.70 of revenue per share, with TTM g…
Accumulation Zones
| Metric |
ABBV |
LULU |
| Zone Low |
$194.28 |
$74.62 |
| Zone High |
$220.18 |
$84.58 |
| In Buy Zone? |
No
|
No
|